Saw Palmetto and Prostate Enlargement — What Does the Latest Cochrane Review Show?

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that progresses with age in the vast majority of men — it affects, to some degree, an estimated more than half of men over 50 and most men over 70. The enlarged gland compresses the urethra, leading to characteristic lower urinary tract symptoms (LUTS): more frequent urination, including at night, a weaker or interrupted stream, a feeling of incomplete bladder emptying, and a sudden, hard-to-control urge to urinate.

This is an important distinction worth making up front, since our knowledge base also covers PSA and prostate cancer screening — a related but fundamentally different topic. BPH is a benign process, not directly linked to an increased cancer risk, although both conditions can coexist in the same man at a similar age and produce partially overlapping symptoms. That's why new or worsening urinary symptoms should always go to a doctor first, not straight to the pharmacy shelf for a supplement.

BPH symptoms themselves are rarely life-threatening, but they can significantly reduce quality of life — disrupting sleep, limiting how comfortably someone can be away from home for extended periods, and becoming a genuine source of frustration. It's precisely this burden, combined with some men's reluctance toward prescription drug therapy or procedures, that created a huge, global market for herbal products promising natural symptom relief — and saw palmetto became the undisputed leader in that market.

Serenoa repens is a small dwarf palm growing along the coast of the southeastern United States, and extract from its berries has for decades been one of the most widely purchased herbal supplements in the world, sold in pharmacies and health stores nearly everywhere as support "for prostate health." This popularity didn't come from nowhere — over the years, smaller studies and reviews suggested some effectiveness, and the proposed mechanism of action sounds convincing on paper.

Among the mechanistic hypotheses proposed is inhibition of the enzyme 5-alpha-reductase, which converts testosterone into dihydrotestosterone (DHT), a form that acts more strongly on prostate tissue — a mechanism conceptually similar to how some prescription drugs for BPH work. Anti-inflammatory action and effects on alpha-adrenergic receptors in the bladder neck and prostate gland have also been proposed. It's worth stating clearly, though: these are mechanistic hypotheses from laboratory and tissue studies, not a proven clinical mode of action — a credible biological mechanism on its own is not yet proof that something actually helps patients in practice.

Cochrane reviews are considered among the most rigorous and trustworthy sources of evidence in all of medicine — they systematically gather and assess the quality of all available randomized trials on a given topic, rather than relying on single, selectively chosen papers. In 2024, Franco and colleagues published an updated version of just such a review, dedicated specifically to the role of Serenoa repens in treating lower urinary tract symptoms related to benign prostatic enlargement.

It's worth pausing on the numbers. The IPSS (International Prostate Symptom Score) scale is a standard, widely used questionnaire for assessing the severity of BPH symptoms, scored from 0 to 35. A difference of -0.90 points between the saw palmetto group and the placebo group is small enough that, in clinical practice, it's hard to speak of a patient-noticeable improvement — and a confidence interval reaching nearly to zero (-1.74 to -0.07) further underscores just how small and uncertain in magnitude this effect is, even if statistically distinguishable from zero.

This distinction matters practically when interpreting many supplement studies, not just saw palmetto. A weak, inconclusive result from a small, poorly designed study leaves room for hope: "maybe with better methodology it would come out differently." A result from a large, updated, high-certainty Cochrane review leaves much less of that room — this isn't a lack of evidence for effectiveness, it's evidence of a lack of meaningful effectiveness.

The Cochrane review contains one important caveat worth mentioning honestly. Phytotherapeutic preparations combining Serenoa repens with other botanical substances were analyzed separately — this group showed a somewhat larger difference in IPSS score (-2.41 points, 95% CI -4.54 to -0.29), but based on only 4 trials with 460 participants and with LOW-certainty evidence, with very substantial uncertainty about the effect on quality of life.

Saw palmetto is a good example of how a supplement's long-standing popularity and a convincing mechanism of action can outpace actual clinical evidence by many years. The updated 2024 Cochrane review isn't a single, controversial study — it's a pooled, rigorous analysis of 27 trials and more than 4,600 men, providing high-certainty evidence. An honest summary of this topic isn't about discrediting everyone who has ever taken this supplement, but about correcting expectations: it's a safe, but most likely not very effective, standalone intervention for BPH symptoms, and not a substitute for proven urological care.